U.S. Markets closed

iCo Therapeutics Inc. (ICO.V)


TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
0.0450.000 (0.000%)
At close: 3:31PM EDT
People also watch
KNE.VBTI.VDMA.VATE.VEKG.V
Full screen
Previous Close0.045
Open0.045
Bid0.045 x
Ask0.050 x
Day's Range0.045 - 0.045
52 Week Range0.030 - 0.090
Volume677,000
Avg. Volume371,130
Market Cap3.8M
Beta3.71
PE Ratio (TTM)-3.75
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile22 days ago

    iCo Therapeutics Announces Election of Directors

    Vancouver, British Columbia--(Newsfile Corp. - June 30, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the election of directors at the annual meeting of shareholders held on June 29, 2017. At the annual meeting of shareholders held on June 29, 2017, Andrew Rae, Susan Koppy, Wiiliam Jarosz and Michael Liggett were elected directors of the Company and will hold office until the next annual general meeting ...

  • Newsfilelast month

    iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset

    Vancouver, British Columbia--(Newsfile Corp. - June 15, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported it will hold a pre IND meeting with the Division of Transplantation and Ophthalmology, US Food and Drug Administration (FDA) on June 21st, 2017. Discussions will focus on a proprietary dual action glaucoma asset with a novel mechanism of action that reduces intraocular pressure (IOP). The target is validated by literature and a ...

  • Newsfilelast month

    iCo Therapeutics Announces Positive Oral Amphotericin Study

    Vancouver, British Columbia--(Newsfile Corp. - June 12, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported the successful conclusion of pre-clinical studies involving its lead oral Amphotericin B candidate, including compelling safety data from its pivotal 14 day GLP (Good Laboratory Practices compliant) toxicology study.Data from its IND enabling 14 day GLP study conducted in Toronto, Ontario facilities revealed that oral administration of Amphotericin B at a dose levels of ...